---
reference_id: "PMID:38983872"
title: Systemic delivery of AAV-GCDH ameliorates HLD-induced phenotype in a glutaric aciduria type I mouse model.
authors:
- Mateu-Bosch A
- Segur-Bailach E
- Muñoz-Moreno E
- Barallobre MJ
- Arbonés ML
- Gea-Sorlí S
- Tort F
- Ribes A
- García-Villoria J
- Fillat C
journal: Mol Ther Methods Clin Dev
year: '2024'
doi: 10.1016/j.omtm.2024.101276
content_type: abstract_only
---

# Systemic delivery of AAV-GCDH ameliorates HLD-induced phenotype in a glutaric aciduria type I mouse model.
**Authors:** Mateu-Bosch A, Segur-Bailach E, Muñoz-Moreno E, Barallobre MJ, Arbonés ML, Gea-Sorlí S, Tort F, Ribes A, García-Villoria J, Fillat C
**Journal:** Mol Ther Methods Clin Dev (2024)
**DOI:** [10.1016/j.omtm.2024.101276](https://doi.org/10.1016/j.omtm.2024.101276)

## Content

1. Mol Ther Methods Clin Dev. 2024 Jun 4;32(3):101276. doi: 
10.1016/j.omtm.2024.101276. eCollection 2024 Sep 12.

Systemic delivery of AAV-GCDH ameliorates HLD-induced phenotype in a glutaric 
aciduria type I mouse model.

Mateu-Bosch A(1), Segur-Bailach E(1)(2), Muñoz-Moreno E(1), Barallobre MJ(1)(3), 
Arbonés ML(1)(3), Gea-Sorlí S(1)(2), Tort F(1)(2)(4), Ribes A(1)(2)(4), 
García-Villoria J(1)(2)(4), Fillat C(1)(2)(5).

Author information:
(1)Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), 08036 
Barcelona, Spain.
(2)Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), 
08036 Barcelona, Spain.
(3)Instituto de Biología Molecular de Barcelona, IBMB-CSIC, Parc Científic de 
Barcelona, 08028 Barcelona, Spain.
(4)Secció d'Errors Congènits del Metabolisme-IBC, Servei de Bioquímica i 
Genètica Molecular, Hospital Clínic, 08028 Barcelona, Spain.
(5)Facultat de Medicina i Ciències de la Salut. Universitat de Barcelona, 08036 
Barcelona, Spain.

Glutaric aciduria type 1 (GA1) is a rare inherited metabolic disorder caused by 
a deficiency of glutaryl-coenzyme A dehydrogenase (GCDH), with accumulation of 
neurotoxic metabolites, resulting in a complex movement disorder, irreversible 
brain damage, and premature death in untreated individuals. While early 
diagnosis and a lysine restricted diet can extend survival, they do not prevent 
neurological damage in approximately one-third of treated patients, and more 
effective therapies are required. Here we report the efficacy of 
adeno-associated virus 9 (AAV9)-mediated systemic delivery of human GCDH at 
preventing a high lysine diet (HLD)-induced phenotype in Gcdh -/- mice. Neonatal 
treatment with AAV-GCDH restores GCDH expression and enzyme activity in liver 
and striatum. This treatment protects the mice from HLD-aggressive phenotype 
with all mice surviving this exposure; in stark contrast, a lack of treatment on 
an HLD triggers very high accumulation of glutaric acid, 3-hydroxyglutaric acid, 
and glutarylcarnitine in tissues, with about 60% death due to brain accumulation 
of toxic lysine metabolites. AAV-GCDH significantly ameliorates the striatal 
neuropathology, minimizing neuronal dysfunction, gliosis, and alterations in 
myelination. Magnetic resonance imaging findings show protection against 
striatal injury. Altogether, these results provide preclinical evidence to 
support AAV-GCDH gene therapy for GA1.

© 2024 The Author(s).

DOI: 10.1016/j.omtm.2024.101276
PMCID: PMC11231595
PMID: 38983872

Conflict of interest statement: The authors declare no competing interests.